Ibrutinib,a Bruton's tyrosine kinase inhibitor,a new risk factor for cryptococcosis |
| |
| Institution: | 1. Infectious diseases department, CHU de Nantes, 1, place Alexis Ricordeau, 44093 Nantes cedex, France;2. INSERM CIC 1413, CHU de Nantes, Nantes, France;3. Parasitology and medical mycology laboratory, CHU de Nantes, Nantes, France;4. Nantes Atlantique Universities, EA1155 IICiMed, Institut de Recherche en Santé 2, Nantes, France;5. Pharmacovigilance, Clinical pharmacology department, CHU de Nantes, Nantes, France;6. Infectious diseases department, CHD de Vendée, La Roche sur Yon, France;7. Hematology department, CHU de Nantes, Nantes, France;8. Microbiological laboratory, CHD de Vendée, La Roche sur Yon, France |
| |
| Abstract: | PurposeInvasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.Patients and methodWe reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.ResultsPatients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.ConclusionClinicians must be aware of this infection in patients with hematological malignancies on ibrutinib. |
| |
| Keywords: | Chronic lymphocytic leukemia Cryptococcosis Ibrutinib |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
